Download
1-s2.0-S0264410X2030788X-main.pdf 625,63KB
WeightNameValue
1000 Titel
  • Landscape analysis of pharmacovigilance and related practices among 34 vaccine manufacturers’ from emerging countries
1000 Autor/in
  1. Hartmann, Katharina |
  2. Pagliusi, Sonia |
  3. Precioso, Alexander |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-06-24
1000 Erschienen in
1000 Quellenangabe
  • 38(34):5490-5497
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1016/j.vaccine.2020.06.016 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311355 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Developing Countries’ Vaccine Manufacturers Network was tasked with the strategic goal of seeking solutions, jointly with manufacturers, for enabling the stable, sustainable supply of quality vaccines to developing countries to increase global immunization. As vaccines are given to millions of healthy people, including children, to prevent life-threatening diseases, vaccines must meet high safety standards. Vaccine safety monitoring is of paramount importance to maintain trust in vaccination programs globally. Once a vaccine is licensed and recommended for use, its safety and effectiveness must be monitored during its whole lifecycle, as the safety profile and protective effectiveness may change over time. A well-established safety governance model across the organization with underlying processes for data collection, signal and risk management and communication is essential. A “fit for purpose” pharmacovigilance system may vary as it depends on several factors. However, all vaccine manufacturers strive to achieve a pharmacovigilance system satisfying Good Pharmacovigilance Practices, in compliance with national, international and supranational requirements, as applicable. A landscape analysis, using a questionnaire covering nine pharmacovigilance key areas related to an effective system, was conducted to understand the existing pharmacovigilance structures, practices and expertise of vaccine manufacturers from emerging countries, on an institutional level. 34 of the 43 contacted manufacturers participated voluntarily. The survey results show that all respondents have established vaccine safety capacity, mainly in collecting and handling adverse events following immunization and implementing standardized processes; the survey also shows differences in the maturity of the manufacturers’ pharmacovigilance system, Quality Management System, signal and risk management, and safety governance. The analysis provides a tool for manufacturers to gain a “bird's-eye” view of the structure of pharmacovigilance key areas and the operational dimensions covered by each area, to benchmarking against international expectations, serving as a basis to further strengthen pharmacovigilance systems, to support accelerated global vaccine supply.
1000 Sacherschließung
lokal Pharmacovigilance
lokal Infectious diseases
lokal Vaccination
lokal Safety
lokal Post-marketing surveillance
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SGFydG1hbm4sIEthdGhhcmluYQ==|https://frl.publisso.de/adhoc/uri/UGFnbGl1c2ksIFNvbmlh|https://orcid.org/0000-0001-8657-9292
1000 Label
1000 Förderer
  1. Bill and Melinda Gates Foundation |
1000 Fördernummer
  1. OPP 1204379
1000 Förderprogramm
  1. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Bill and Melinda Gates Foundation |
    1000 Förderprogramm -
    1000 Fördernummer OPP 1204379
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6429953.rdf
1000 Erstellt am 2021-10-21T11:53:45.193+0200
1000 Erstellt von 218
1000 beschreibt frl:6429953
1000 Bearbeitet von 218
1000 Zuletzt bearbeitet 2022-10-27T08:37:53.721+0200
1000 Objekt bearb. Thu Oct 27 08:37:53 CEST 2022
1000 Vgl. frl:6429953
1000 Oai Id
  1. oai:frl.publisso.de:frl:6429953 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source